Table 1.
Patient demographic and clinical characteristics
| MRONJ patients n = 30 |
Cohort antiresorptive n = 43 |
Control no antiresorptive n = 6 |
All patients n = 49 |
||||||
|---|---|---|---|---|---|---|---|---|---|
| Variable | Category | n | (%) | n | (%) | n | (%) | n | (%) |
| Sex | Male | 9 | (30) | 11 | (26) | 1 | (17) | 12 | (24) |
| Female | 21 | (70) | 32 | (74) | 5 | (83) | 37 | (76) | |
| Age | ≤ 60 years | 7 | (23) | 10 | (23) | 5 | (83) | 15 | (31) |
| > 60 years | 23 | (77) | 33 | (77) | 1 | (17) | 34 | (69) | |
| Primary disease | Osteoporosis | 9 | (30) | 19 | (44) | ||||
| Cancer | 21 | (70) | 24 | (56) | |||||
| Antiresorptive class | Bisphosphonates | 15 | (50) | 23 | (54) | ||||
| Denosumab | 15 | (50) | 20 | (46) | |||||
| Antiresorptive agents | Zoledronic acid (Zometa) | 11 | (37) | 12 | (28) | ||||
| Alendronate (Fosamax) | 4 | (13) | 11 | (25) | |||||
| Denosumab (Prolia) | 5 | (17) | 8 | (19) | |||||
| Denosumab (Xgeva) | 10 | (33) | 12 | (28) | |||||
| Administration period | ≤ 36 months | 19 | (63) | 24 | (56) | ||||
| > 36 months | 11 | (37) | 19 | (44) | |||||
| Site of MRONJ | Maxilla | 12 | (40) | ||||||
| Mandible | 18 | (60) | |||||||
| Staging of MRONJ | Stage 1 | 10 | (33.3) | ||||||
| Stage 2 | 10 | (33.3) | |||||||
| Stage 3 | 10 | (33.3) | |||||||
MRONJ=Medication-Related Osteonecrosis of the Jaw.